PA
PASG.US Passage Bio Inc
- Market cap
- USD 13.3M
- P/E
- -
- P/B
- 273.51x
- ROE
- -53,597.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PASG.US undervalued?
Graham numberThe Graham number of Passage Bio Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Passage Bio Inc fundamental analysis
No fundamental analysis for Passage Bio Inc yet.
Passage Bio Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatmen…
Full company profilePassage Bio Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Passage Bio Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -134K | -800K | -1.54M | -3.68M | -3.72M | -3.08M | -728K | - |
| Operating Income | -13.5M | -37.2M | -113M | -186M | -138M | -100M | -70.4M | -43.2M | -29.5M |
| EBITDA | -7.42M | -36.6M | -111M | -176M | -132M | -98.3M | -62.1M | -44.8M | -26.6M |
| Net Income | -12.8M | -45.6M | -112M | -185M | -136M | -102M | -64.8M | -45.5M | -26.8M |
| EPS | -11 | -38 | -49 | -70 | -50 | -37 | -21 | -14 | -8.33 |
| Balance Sheet | |||||||||
| Total Assets | 33.5M | 179M | 328M | 355M | 244M | 151M | 102M | 62.3M | 20.8M |
| Total Liabilities | 45.6M | 4.26M | 23.3M | 36.4M | 42.2M | 39.3M | 41.2M | 43.5M | 20.7M |
| Shareholders' Equity | -12.2M | 174M | 305M | 319M | 201M | 111M | 61.3M | 18.8M | 50.0K |
| Cash & Short-term Investments | 24.9M | 159M | 305M | 316M | 190M | 114M | 76.8M | 46.3M | 20.2M |
| Total Debt | - | - | - | - | 27.1M | 26.3M | 25.5M | 24.0M | - |
| Cash Flow | |||||||||
| Operating Cash Flow | -18.6M | -39.9M | -80.5M | -127M | -118M | -78.3M | -48.0M | -31.5M | -34.9M |
| Capital Expenditure | 2.54M | 1.69M | 1.65M | 25.6M | 5.27M | 146K | 34.0K | 0.00 | 0.00 |
| Free Cash Flow | -21.1M | -41.6M | -82.2M | -153M | -123M | -78.4M | -48.0M | -31.5M | -34.9M |
| Ratios | |||||||||
| ROE | - | -26.2% | -36.8% | -58.2% | -67.6% | -91.7% | -105.7% | -242.7% | -53,597.3% |
| ROA | -38.2% | -25.5% | -34.2% | -52.2% | -55.9% | -67.8% | -63.2% | -73.1% | -128.9% |
| Debt to Equity | - | - | - | - | 0.13x | 0.24x | 0.42x | 1.28x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Passage Bio Inc dividends
Passage Bio Inc has not paid dividends in the last 8 fiscal years.
Last stock split: 1:20 on Jul 14, 2025.
Who owns Passage Bio Inc
- Insiders 7.72%
- Institutions 49.13%
- Public & others 43.15%
- Shares outstanding 3.22M
- Free float 3.20M
Top funds holding PASG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 37.5K | 1.17% | -52.34% | Sep 2026 |
| Fidelity Extended Market Index | 17.0K | 0.53% | -0.38% | Sep 2026 |
| Abante Quant Value FI | 14.1K | 0.44% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 6.43K | 0.20% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 4.78K | 0.15% | 0.00% | Sep 2026 |
| ERSTE STOCK BIOTEC EUR R01 A | 2.79K | 0.09% | 0.00% | Aug 2026 |
| LVIP Dimensional US Core Equity 2 Std | 2.02K | 0.06% | 0.00% | Sep 2026 |
| DFA US Core Equity Class F | 1.50K | 0.05% | 0.00% | Aug 2026 |
| Fidelity Nasdaq Composite Index | 1.27K | 0.04% | 0.00% | Aug 2026 |
| DFA US Vector Equity Class F | 1.22K | 0.04% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 638.00 | 0.02% | 0.00% | Sep 2026 |
| BlackRock Diversified Equity Alpha Inst | 504.00 | 0.02% | 0.00% | Jul 2026 |
| Guggenheim Active Allocation Fund | 22.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding PASG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Lynx1 Capital Management, LP | 674K | 20.94% | +8.03% | Jun 2026 |
| Vanguard Capital Management, LLC | 114K | 3.54% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 107K | 3.33% | 0.00% | Jun 2026 |
| Ikarian Capital, LLC | 99.5K | 3.09% | +46.08% | Jun 2026 |
| Yiheng Capital LLC | 86.1K | 2.68% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 46.9K | 1.46% | -2.09% | Sep 2026 |
| Erste Asset Management GmbH | 40.7K | 1.26% | -52.31% | Jun 2026 |
| Geode Capital Management, LLC | 37.0K | 1.15% | -10.52% | Jun 2026 |
| Verdad Advisers, LP | 30.7K | 0.95% | +38.86% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 28.4K | 0.88% | +50.70% | Jun 2026 |
| BlackRock Inc | 27.9K | 0.87% | -2.40% | Jun 2026 |
| Acadian Asset Management LLC | 22.5K | 0.70% | 0.00% | Sep 2026 |
| Vanguard Fiduciary Trust Co | 17.0K | 0.53% | 0.00% | Jun 2026 |
| Deltec Asset Management LLC | 15.0K | 0.47% | 0.00% | Jun 2026 |
| UBS Group AG | 13.6K | 0.42% | -50.67% | Jun 2026 |
| HRT FINANCIAL LLC | 12.7K | 0.40% | 0.00% | Jun 2026 |
| Fiduciary Trust Co | 10.8K | 0.33% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.39K | 0.07% | -9.85% | Jun 2026 |
| Vanguard Global Advisers, LLC | 638.00 | 0.02% | 0.00% | Jun 2026 |
| Barclays PLC | 212.00 | 0.01% | 0.00% | Jun 2026 |
Passage Bio Inc company profile
- Company name
- Passage Bio Inc
- Ticker
- PASG.US
- Exchange
- USA Stocks
- Listed since
- Feb 28, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 24
- Fiscal year end
- December
- Address
- One Commerce Square, Philadelphia, PA, United States, 19103
- Phone
- 267 866 0311
- Website
- passagebio.com
About Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Passage Bio Inc management
2- Dr. William Chou M.D., Ph.D.President, CEO & Director · born 1973
- Ms. Kathleen BorthwickSenior VP, CFO, Principal Financial Officer & Principal Accounting Officer · born 1977